Table 1.

Patient characteristics

SexAgeHistologic RCC subtypeMSKCC risk scorea,bNumber of prior regimensTreatment duration on prior VEGF-targeted agent (months; agent)Number of metastatic sitesRapalogTreatment duration on rapalog (months)
1F58ClearInt114 (sunitinib)≥3Temsirolimus27
2F73ClearInt13 (sunitinib)c1Temsirolimus34
3M66ClearInt25 (sunitinib)≥3Everolimus20
4F60ClearFav311 (sunitinib)≥3Temsirolimus28
5F50UnclassifiedFav12 (sunitinib)≥3Temsirolimus45+

Abbreviations: Fav, favorable; Int, intermediate; MSKCC, Memorial Sloan-Kettering Cancer Center

  • aAt the time of first rapalog dose.

  • bMotzer et al., J Clin Oncol 1999;17:2530–40.

  • cDiscontinued due to treatment toxicity.